Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome + bevacizumab with concurrent radiotherapy for recurrent high-grade glioma
ChiCTR2600121489Phase 4Not yet recruiting
- Sponsor
- Anqing Municipal Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan liposome and bevacizumab in glioma, sponsored by Anqing Municipal Hospital. Primary endpoint: Objective response rate (ORR). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
irinotecan liposomebevacizumab
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR2600121489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121489.